Glioblastoma Multiforme
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Some of these genetic alterations are currently believed to have clinical significance and are more related to secondary GBMs: TP53 mutations, detectable in the early stages of secondary GBM (found in 65%), isocitrate dehydrogenase 1/2 mutations (50% of secondary GBMs), and also O6-methylguanine-DNA methyltransferase promoter methylation (75% of secondary GBMs).
|
31550738 |
2020 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
We studied the association of immunohistochemical expression of hypoxia inducible factor-1 alpha (HIF-1α), telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1) and tumor protein p53 with overall survival (OS) in glioblastoma patients uniformly treated by standard of care, with adequate follow-up.
|
31258744 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our recent study indicated that TSN has anti-cancer effect in glioblastoma through induction of estrogen receptor β (ERβ) and p53.
|
29629572 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
Specifically, targeting cellular pathways frequently altered in glioblastoma, such as the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), the p53 and the retinoblastoma (RB) pathways, or epidermal growth factor receptor (EGFR) gene amplification or mutation, have failed to improve outcome, likely because of redundant compensatory mechanisms, insufficient target coverage related in part to the blood brain barrier, or poor tolerability and safety.
|
31541850 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
We found that HR indeed regulates p53 target genes, including those implicated in cell cycle progression and apoptosis in the GBM-derived U87 cell line, and restoring HR expression triggered G2/M arrest and apoptosis.
|
30191601 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.
|
30940658 |
2019 |
Glioblastoma Multiforme
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The test results of DWI and MRS of patients with GBM can accurately reflect the inactivation or mutation of PTEN and p53.
|
29745082 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
To determine whether there is a threshold for the TMZ-induced DNA damage response and exploring the factors regulating the switch between p53 dependent survival and death, the glioblastoma lines LN-229 (deficient in MGMT) and LN-229MGMT (stably transfected with MGMT) were exposed to different doses of TMZ. p53 protein expression and phosphorylation levels of p-p53ser15 and p-p53ser46 were determined by Western blotting.
|
30925722 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma.
|
30594071 |
2019 |
Glioblastoma Multiforme
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Mean Ki-67 labeling index was 29% (range, 1.5%-80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%).
|
31003026 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway.
|
31001122 |
2019 |
Glioblastoma Multiforme
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Role of asparagine endopeptidase in mediating wild-type p53 inactivation of glioblastoma.
|
31400201 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
Impairment of IMPDH2 activity triggers nucleolar stress and growth arrest of glioblastoma cells even in the absence of functional p53.
|
31371825 |
2019 |
Glioblastoma Multiforme
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of MTBP in the biology of TP53-wildtype (TP53wt) GBMs.
|
31534534 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
|
31241175 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
Quantitative morphological tumor characteristics on post-contrast T1-weighted MRI can to a certain degree provide insights regarding Ki67 and p53 status in patients with glioblastoma.
|
31020343 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
Combined techniques of cryo-electron microscopy (EM) and molecular modeling reveal a new modified form of the p53 tumor suppressor present in aggressive glioblastoma multiforme cancer cells.
|
30963664 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
|
31081046 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
This antagonism results in increased p53 activity and can also re-activates the p53 pathway and resensitize the glioblastoma cells to apoptosis.
|
30656973 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
We used CRN2 knock-out mice for analyses as well as for crossbreeding with a Tp53/Pten knock-out glioblastoma mouse model.
|
31677819 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
In this study, biotinylated PAMAM G3 dendrimers substituted with the recognized anticancer agents cyclooxygenase-2 (COX-2) inhibitor celecoxib and peroxisome proliferator-activated receptor γ (PPARγ) agonist Fmoc-L-Leucine (G3-BCL) were tested in vitro on human cell lines with different p53 status: glioblastoma (U-118 MG), normal fibroblasts (BJ) and immortalized keratinocytes (HaCaT).
|
31652556 |
2019 |
Glioblastoma Multiforme
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The Kaplan-Meier survival plot illustrated poor survival in glioblastoma patients with over-expressed LINC-ROR ( P=0.010) and down-regulated p53 ( P=0.002).
|
30852975 |
2019 |
Glioblastoma Multiforme
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our study identified BRCA1 as a potential target that sensitizes TMZ-induced cell death in P53 wild-type GBM, suggesting that the combined inhibition of BRCA1 and TMZ treatment will be a successful targeted therapy for GBM patients.
|
31815044 |
2019 |
Glioblastoma Multiforme
|
0.200 |
Biomarker
|
disease |
BEFREE |
More than 1700 proteins were quantified, and bioinformatics predicted activations of MYC, NFE2L2, FN1, and TGFβ1 and inhibition of TP53 in GBM-EV stimulated astrocytes that were then confirmed by qPCR.
|
30353492 |
2019 |
Glioblastoma Multiforme
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Most importantly, the levels of Sirtuin 3 (SIRT3) and phosphorylated p53 were also downregulated, indicating that Pt3glc combinated with PI3K inhibitor could induce GBM cell death may act via the SIRT3/p53-mediated mitochondrial and PI3K/Akt-ERK pathways.
|
29336479 |
2019 |